Regardless of the underlying CD8+ tolerance mechanism (deletion versus exhaustion), neither is reversible through immune checkpoint blockade therapy, which may help to explain the disappointing efficacy of anti-PD-1 monotherapy in patients with acute leukemia (Berger et al., 2008). Here, CD8A is linked to acute leukemia.